-0.000165535507366297 -0.000331071014732712 -0.00463499420625726 -0.00686972355570268 -0.016553550736633 -0.0184572090713458 -0.0254924681344148 -0.0219334547260388
Sign Up Today X
Thanks for submitting the form.
Stockreport

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance]

BioMarin Pharmaceutical Inc. (BMRN)  More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Under the terms of the agreement, BioMarin will pay cash for all of Amicus' shares for a total consideration of $4.8bn. This deal will set BioMarin back $14.50 per share, constituting a 33% premium on Amicus' $10.89 18 December stock value at market close. BioMarin's stock has increased 17.71% on the acquisition, from an 18 December close of $51.95 to a 19 December close of $61.15. This multi-billion-dollar deal, which is the biggest in BioMarin's history, will give the pharma rights to Amicus' Fabry disease therapy, Galafold (migalastat), which has been on the US market since 2018. In 2024, the drug brought in $458.1m for Amicus, an 18% increase on 2023. Galafold is currently the only US Food and Drug Administration (FDA) approved chaperone therapy for Fabry disease – a rare genetic disorder characterised by the buildup of fatty substrates in the cells of an affected patient. Following a US patent litigation with generics giant Teva Pharmaceuticals, Galafold now holds market [Read more]
IMPACT SNAPSHOT EVENT TIME: BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BMRN alerts
from News Quantified
BMRN
NEWS
BMRN
Earnings
BMRN
Analyst Actions
BMRN
SEC Filings
Stockreport

BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push [Yahoo! Finance]

BioMarin Pharmaceutical Inc.  (BMRN) 
More Company Research Source: Yahoo! Finance
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com
Under the terms of the agreement, BioMarin will pay cash for all of Amicus' shares for a total consideration of $4.8bn. This deal will set BioMarin back $14.50 per share, constituting a 33% premium on Amicus' $10.89 18 December stock value at market close. BioMarin's stock has increased 17.71% on the acquisition, from an 18 December close of $51.95 to a 19 December close of $61.15. This multi-billion-dollar deal, which is the biggest in BioMarin's history, will give the pharma rights to Amicus' Fabry disease therapy, Galafold (migalastat), which has been on the US market since 2018. In 2024, the drug brought in $458.1m for Amicus, an 18% increase on 2023. Galafold is currently the only US Food and Drug Administration (FDA) approved chaperone therapy for Fabry disease – a rare genetic disorder characterised by the buildup of fatty substrates in the cells of an affected patient. Following a US patent litigation with generics giant Teva Pharmaceuticals, Galafold now holds market [Read more]
IMPACT SNAPSHOT
EVENT TIME:
BMRN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS